GET DAILY SIGNALSGinkgo Bioworks (DNA) Falls -18% Over 30 Days Amid Sharp Volatility
Key Takeaways
- Ginkgo Bioworks shares have fallen roughly 18% over the past 30 days, slipping from about $12.35 in early October to near $10.08.
- The decline follows a sharp, momentum-driven rally that carried the stock to an intraday 52-week high of $18.22 before profit-taking set in.
- Investor enthusiasm around AI-driven drug discovery and autonomous-lab partnerships has been tempered by persistent losses and valuation concerns.
- Wall Street maintains a cautious stance, with a consensus "Sell" rating and an average 12-month price target of $8.00 across three analysts.
- The company's next quarterly earnings report, expected in early November 2026, is a key near-term catalyst for the stock.
- Over the trailing quarter, the stock remains higher versus its early-August level, reflecting unusually high volatility in both directions.
- For additional context, investors can review DNA's Price Targets, Earnings, and Forecast pages to explore analyst expectations and forward-looking data.
- Readers can also explore Trending AI Robots to see how algorithmic trading strategies are positioned across the market.
Ginkgo Bioworks (DNA) Company Overview and Market Position
Ginkgo Bioworks Holdings, Inc. is a Boston-based cell engineering and synthetic biology company founded in 2008. The company operates a platform that programs cells for customers across pharmaceuticals, agriculture, industrial, food, and government and defense markets. Its offerings include cell engineering research and development solutions, the Ginkgo Datapoints biological data-generation service, and reconfigurable automation systems, anchored by its Nebula autonomous laboratory and Ginkgo Cloud Lab.
Ginkgo went public in September 2021 through a merger with a special purpose acquisition company. In 2026, the company completed the divestiture of its Biosecurity segment to refocus on its core cell engineering business and autonomous-lab infrastructure. Investors follow DNA closely for its positioning at the intersection of synthetic biology, laboratory automation, and AI-driven drug discovery, while also weighing its history of operating losses and declining revenue against that strategic pivot. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Ginkgo Bioworks (DNA) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, DNA has moved from a closing price of roughly $12.35 in early October to about $10.08, a decline of approximately 18%. The move has been anything but linear. The stock spiked above $14 in the first week of October and touched an intraday high of $18.22 before retreating through the remainder of the month, including a double-digit percentage pullback in recent trading.
The trailing three-month picture is more mixed. Measured against its early-August level of about $8.94, DNA is still up roughly 13% over the quarter. That gain, however, reflects a powerful late-September and early-October surge — at one point the shares were up well over 100% in a matter of weeks — that has since been partially unwound. The 52-week range of $5.37 to $18.22 underscores the stock's extreme volatility. From what I see, this kind of swing highlights why tracking patterns with tools like Tickeron’s AI Pattern Search Engine can add useful perspective.
What Drove DNA Stock Price in the Last 30 Days
The recent decline primarily reflects a reversal of momentum after an outsized rally. Enthusiasm around Ginkgo's AI and autonomous-lab story, reinforced by a September partnership between its Ginkgo Datapoints unit and Eli Lilly's (LLY) TuneLab, helped fuel a sharp run-up into early October. Additional announcements, including in-kind access to its Boston autonomous laboratory for the National Science Foundation's X-Labs program and the integration of Araceli Biosciences' high-content imaging into Nebula, extended the narrative-driven buying.
As the rally peaked, valuation concerns came to the forefront. Commentary questioning whether the share price had "outrun the business" circulated, and profit-taking accelerated. The pullback was compounded by a broadly cautious sell-side stance: three analysts maintain an average price target of $8.00, well below the stock's early-October peak, with ratings skewing toward sell. The stock's recent slide also reflects a return toward fundamentals after a period in which price appreciation outpaced reported revenue, which continued to decline year over year.
What Drove DNA Stock Performance Over the Last Quarter
The broader quarterly trend has been defined by a dramatic recovery from August lows followed by consolidation. DNA traded near $6.50 to $7.00 for much of August and early September, pressured by weak financial results and an ongoing strategic transition. In the first quarter of 2026, revenue fell roughly 49% year over year while the company completed the divestiture of its Biosecurity business.
Sentiment shifted in late September as investors rotated toward AI-enabled biotechnology and laboratory automation themes. A stronger second-quarter topline result and accelerated cost reductions supported the rebound, and the Lilly TuneLab partnership added a tangible AI drug-discovery catalyst. The stock's subsequent retreat reflects a market reassessing how quickly these initiatives can translate into sustainable revenue and profitability, leaving DNA well above its summer lows but sharply below its recent peak.
DNA Stock Forecast Drivers: What Investors Should Watch Next
Investors will be watching Ginkgo's next quarterly earnings report, expected in early November 2026, for updates on revenue trajectory, cash burn, and progress toward narrowing losses. Guidance on the cell engineering and autonomous-lab businesses will be closely scrutinized, as will any additional commercial partnerships in AI-driven drug discovery.
Key variables include the pace of adoption of Ginkgo's automation and data-services offerings, the company's cash runway, and its path toward profitability. Analyst expectations remain cautious, with a consensus "Sell" rating and an average price target of $8.00. Broader sector sentiment toward small-cap biotechnology, AI-related names, and interest-rate expectations could also influence DNA's volatility going forward. I'm watching this closely as the earnings date approaches.
Using Tickeron AI Tools in My Analysis
In my own research process, I frequently turn to Tickeron’s AI tools to cross-check market signals and compare positioning across similar names. One platform I find particularly helpful is the AI Screener, which lets me quickly filter for stocks with comparable volatility profiles and sector themes. It helps me stay objective when momentum shifts occur, without replacing my own judgment on fundamentals.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DNA sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for DNA moved above the 200-day moving average on October 07, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on DNA as a result. In 74 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for DNA just turned positive on October 29, 2026. Looking at past instances where DNA's MACD turned positive, the stock continued to rise in 45 of 51 cases over the following month. The odds of a continued upward trend are 88%.
Following a +32.93% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 90 of 109 cases where DNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.
Bearish Trend Analysis
The 10-day RSI Indicator for DNA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 20 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 52 cases where DNA's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
DNA broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.796) is normal, around the industry mean (3.162). P/E Ratio (-2.242) is within average values for comparable stocks, (-1.064). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.622) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 88 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement